Epidiolex

It was another extremely busy week for the cannabis industry. Voters in Oklahoma chose to legalize medical marijuana, becoming the 30th U.S. state to do so; GW Pharmaceuticals (NASDAQ: GWPH) got the first-ever FDA approval for a cannabis-based drug; Ice Cube’s Big3 basketball league...

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) made history Monday when the company’s Epidiolex became the first cannabis-based drug ever approved by the FDA. New Cannabis Ventures and 420 Investor founder Alan Brochstein joined the PreMarket Prep trading show on Tuesday to discuss the...

As expected, the U.S. Food and Drug Administration on Monday approved GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH)'s Epidiolex for the treatment of epilepsy, specifically for people who suffer with Lennox-Gastaut and Dravet syndromes. Why It’s Important The drug is derived from the...

The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved by the agency previously, either as a single ingredient drug, or as part of a...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) were halted Thursday, ahead of a Food and Drug Administration vote on the company's cannabis-derived drug Epidiolex. Trading resumed after the FDA advisory panel voted unanimously in favor of approving the medicine for the treatment of two...

Medical journal The Lancet published an article Wednesday that could mold the future of cannabis-derived therapeutics. The piece in question featured results from GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) and Greenwich Biosciences’ Phase 3 study of Epidiolex — an oral cannabidiol...

2017 had a bullish tone, as assets across categories shone the brightest, although cryptocurrency could be singled out as the standout performer. Marijuana stocks also joined the party, as reflected by the 18.5-percent advance by the U.S. Marijuana Index. Momentum Extending Into The New Year...

Despite early fears, it turned out 2017 was a pretty hot year for marijuana stocks. “This is a year where the patient were rewarded, which is not that surprising to me,” Alan Brochstein, founder of 420 Investor, said Dec. 28 on Benzinga's PreMarket Prep. Alarms were raised as...

Shares of cannabinoid-focused biotech company GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) are "on a path to new highs," according to Goldman Sachs. The Analyst Goldman Sachs analyst Salveen Richter upgraded GW Pharma from Neutral to Buy and lifted her price target to $174, suggesting...